Correction: Bio-Works receives order for WorkBeads™ affimAb valued at approximately SEK 8.3 million

This press release was wrongfully not tagged as information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

Bio-Works Technologies AB today announces that the company has received an order from a returning customer in Europe for 69 liters of WorkBeads™ affimAb, valued at approximately SEK 8.3 million. Deliveries are scheduled for the first and second quarters of 2026.

The order confirms continued trust from the customer and underscores Bio-Works’ strong position as a supplier of high-quality chromatography products to the biotechnology and biopharmaceutical industries.

“Receiving this repeat order from an established customer is clear proof that our products deliver on quality and performance. We are proud to continue contributing to our customers’ success in the development and production of biological drugs,” says Lone Poulsen Carlbom, CEO of Bio-Works.

WorkBeads™ affimAb is a chromatography medium developed for the purification of monoclonal antibodies (mAbs) and other protein-based drugs, where high affinity and robust performance are critical.

This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-10-2025 09:36 CET.